SSY Group's (HKG:2005) glycerol fructose and sodium chloride injection has passed China's National Medical Products Administration's consistency evaluation of quality and efficacy of generic drugs, a Monday bourse filing said.

The injection is used mainly for the treatment of acute or chronic intracranial pressure increase and cerebral edema which are caused by cerebrovascular disease, brain trauma, brain tumors, and intracranial inflammation among other conditions.

Shares of the pharmaceutical company were down nearly 5% in recent trade.